These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20494220)

  • 21. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
    Arbyn M; Dillner J
    J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasia.
    Pathirana D; Hillemanns P; Petry KU; Becker N; Brockmeyer NH; Erdmann R; Gissmann L; Grundhewer H; Ikenberg H; Kaufmann AM; Klusmann J; Kopp I; Pfister H; Rzany B; Schneede P; Schneider A; Smola S; Winter-Koch N; Wutzler P; Gross G
    Vaccine; 2009 Jul; 27(34):4551-9. PubMed ID: 19524337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Introducing human papillomavirus vaccines - questions remain.
    Paavonen J; Lehtinen M
    Ann Med; 2008; 40(3):162-6. PubMed ID: 18382882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cervical cancer prevention in the human papilloma virus vaccine era.
    Ghazal-Aswad S
    Ann N Y Acad Sci; 2008 Sep; 1138():253-6. PubMed ID: 18837904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.
    Broomall EM; Reynolds SM; Jacobson RM
    Postgrad Med; 2010 Mar; 122(2):121-9. PubMed ID: 20203463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [HPV vaccination: principles, results and future perspectives].
    Rouzier R; Uzan C; Collinet P
    J Gynecol Obstet Biol Reprod (Paris); 2007 Feb; 36(1):13-8. PubMed ID: 17293248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overcoming barriers to adherence to HPV vaccination recommendations.
    Dempsey AF; Davis MM
    Am J Manag Care; 2006 Dec; 12(17 Suppl):S484-91. PubMed ID: 17203992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human papillomavirus, cervical cancer, and the vaccines.
    Tovar JM; Bazaldua OV; Vargas L; Reile E
    Postgrad Med; 2008 Jul; 120(2):79-84. PubMed ID: 18654072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diseases caused by human papillomaviruses (HPV).
    Handisurya A; Schellenbacher C; Kirnbauer R
    J Dtsch Dermatol Ges; 2009 May; 7(5):453-66; quiz 466, 467. PubMed ID: 19302229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protecting the next generation: what is the role of the duration of human papillomavirus vaccine-related immunity?
    Günther OP; Ogilvie G; Naus M; Young E; Patrick DM; Dobson S; Duval B; Noël PA; Marra F; Miller D; Brunham RC; Pourbohloul B
    J Infect Dis; 2008 Jun; 197(12):1653-61. PubMed ID: 18513154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccines for preventing HPV-related anogenital infection and neoplasia.
    Ferris DG
    J Am Osteopath Assoc; 2006 Mar; 106(3 Suppl 1):S9-13. PubMed ID: 16729555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
    Adams M; Jasani B; Fiander A
    Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protecting our patients from HPV and HPV-related diseases: the role of vaccines.
    Mahoney MC
    J Fam Pract; 2006 Nov; Suppl():10-7. PubMed ID: 17366753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunobiology of HPV and HPV vaccines.
    Stanley M
    Gynecol Oncol; 2008 May; 109(2 Suppl):S15-21. PubMed ID: 18474288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types.
    Herrero R
    J Infect Dis; 2009 Apr; 199(7):919-22. PubMed ID: 19236278
    [No Abstract]   [Full Text] [Related]  

  • 38. Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review.
    Ault KA
    Obstet Gynecol Surv; 2006 Jun; 61(6 Suppl 1):S26-31. PubMed ID: 16729901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Annual disease burden due to human papillomavirus 16 and 18 infections in Finland.
    Syrjänen KJ
    Scand J Infect Dis Suppl; 2009; 108():2-32. PubMed ID: 19939209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human papillomavirus vaccines: a warty problem.
    Galloway DA
    Infect Agents Dis; 1994 Aug; 3(4):187-93. PubMed ID: 7827787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.